Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects

β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) is required for the production of β‐amyloid peptides, which are implicated in the etiology of Alzheimer's disease. The safety and pharmacokinetics of the BACE1 inhibitor verubecestat have previously been studied in young adults aged 19–...

Descripción completa

Detalles Bibliográficos
Autores principales: Forman, Mark, Palcza, John, Tseng, Jack, Stone, Julie A., Walker, Brittany, Swearingen, Dennis, Troyer, Matthew D., Dockendorf, Marissa F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742941/
https://www.ncbi.nlm.nih.gov/pubmed/31215755
http://dx.doi.org/10.1111/cts.12645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742941/
https://www.ncbi.nlm.nih.gov/pubmed/31215755
http://dx.doi.org/10.1111/cts.12645

Ejemplares similares